Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Cyclacel Pharmaceuticals, Inc (CYCC)

Pharmaceutical Preparations

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/28/2006

Market Cap

1,832,294

Shares Outstanding

1,010,000

Weighted SO

1,019,310

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ELYM --.--%

IKNA --.--%

OVID --.--%

CNTB --.--%

EWTX --.--%

RZLT --.--%

CYT --.--%

XOMAO --.--%

PTIX --.--%

Beta

0.5880

Last Div

0.0000

Range

1.22-11.4

Chg

-0.0678

Avg Vol

132656

Mkt Cap

1832294

Exch

NASDAQ

Country

US

Phone

908 517 7330

DCF Diff

0.6196

DCF

1.6204

Div Yield

0.0000

P/S

24.1079

EV Multiple

-0.0914

P/FV

1626.7281

Div Yield %

0.0000

P/E

-0.1135

PEG

-0.0064

Payout

-0.0070

Current Ratio

1.0725

Quick Ratio

1.0725

Cash Ratio

0.8350

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

101.7921

CCC

-101.7921

Gross Margin

0.7763

Op Margin

-261.6738

Pretax Margin

-263.4106

Net Margin

-188.3750

Eff Tax Rate

0.2849

ROA

-1748.1388

ROE

-20.8024

ROCE

-19809.0209

NI/EBT

0.7151

EBT/EBIT

1.0066

EBIT/Rev

-261.6738

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-184.1983

CF/Debt

0.0000

Equity Multi

8.1982

Rec Turnover

0.0000

Pay Turnover

3.5857

Inv Turnover

0.0000

FA Turnover

1085.7714

Asset Turnover

9.2801

OCF/Share

-6.4949

FCF/Share

-6.4949

Cash/Share

0.0046

OCF/Sales

-110.9021

FCF/OCF

1.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

-84.2900

P/BV

1626.7281

P/B

1626.7281

P/S

24.1079

P/E

-0.1135

P/FCF

-0.2174

P/OCF

-0.1928

P/CF

-0.1928

PEG

-0.0064

P/S

24.1079

EV Multiple

-0.0914

P/FV

1626.7281

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 15, 04:50 CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE GlobeNewswire Inc. Jan 02, 09:15 Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024 GlobeNewswire Inc. Dec 22, 09:15 Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire Inc. Nov 30, 09:15 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC GlobeNewswire Inc. Nov 28, 17:15 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q GlobeNewswire Inc. Nov 28, 17:15 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q GlobeNewswire Inc. Nov 07, 09:15 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Revenue Product Segmentation